Literature DB >> 15017231

A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.

Savino M Di Stasi1, Antonella Giannantoni, Robert L Stephen, Giovanni Capelli, Arcangelo Giurioli, Emmanuele A Jannini, Giuseppe Vespasiani.   

Abstract

PURPOSE: Uncontrolled studies with intraplaque electromotive administration of verapamil and dexamethasone have demonstrated objective improvements in Peyronie's disease. We performed a prospective controlled study to assess the efficacy of intraplaque electromotive verapamil/dexamethasone vs electromotive lidocaine.
MATERIALS AND METHODS: Patients with Peyronie's disease were randomized into a study group (47 patients) and a control group (49 patients). For each treatment session an electrode receptacle was sited over the plaque and filled with either 5 mg verapamil and 8 mg dexamethasone (study group) or 2% lidocaine (control group), and a 2.4 mA electric current was applied for 20 minutes. All patients were scheduled for 4 sessions per week for 6 weeks. Assessment before and after treatment included measurements of plaque volume and penile curvature, and pain on erection (from questionnaire).
RESULTS: A total of 37 patients in the study group and 36 in the control group completed treatment courses. In the study group there were significant decreases in median plaque volume from 824 to 348 mm, and in penile curvature from 43 to 21 degrees. In the control group median volume and curvature were unchanged. The difference in results after treatment between the 2 groups was also significant. Significant pain relief occurred in both groups, transient in the control group and permanent in the study group. All patients experienced temporary erythema at the electrode site. There were no other side effects.
CONCLUSIONS: Intraplaque electromotive verapamil and dexamethasone induce substantial objective improvement in Peyronie's disease compared to electromotive lidocaine administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15017231     DOI: 10.1097/01.ju.0000116450.82816.2c

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Peyronie's Disease: Nonsurgical Therapy Options.

Authors:  Franklin E Kuehhas; Peter Weibl; Tosev Georgi; Nenad Djakovic; Ralf Herwig
Journal:  Rev Urol       Date:  2011

2.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 3.  Treatment of Peyronie's disease: 2012 update.

Authors:  Ege Can Serefoglu; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 4.  2013-2014 updates in Peyronie's disease management.

Authors:  Benjamin A Sherer; Krishnan Warrior; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2014-12       Impact factor: 3.092

Review 5.  Update on medical management of Peyronie's disease.

Authors:  Ronny B W Tan; Premsant Sangkum; Gregory C Mitchell; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

Review 6.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

Review 7.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.

Authors:  Mohammad Hatampour; Karim Sohrabi; Hamid Mazdak; Keyvan Ghadimi; Hanieh Salehi; Reza Kazemi
Journal:  Am J Clin Exp Urol       Date:  2022-02-15

9.  The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.

Authors:  Can Tuygun; Ugur Hakki Ozok; Adnan Gucuk; I Halil Bozkurt; M Abdurrahim Imamoglu
Journal:  Int Urol Nephrol       Date:  2008-07-01       Impact factor: 2.370

10.  Risk factors for emotional and relationship problems in Peyronie's disease.

Authors:  James F Smith; Thomas J Walsh; Simon L Conti; Paul Turek; Tom Lue
Journal:  J Sex Med       Date:  2008-07-14       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.